Skip to main content
. 2019 Dec 4;10(12):917. doi: 10.1038/s41419-019-2156-2

Fig. 1. MCL-1 represents amongst the BCL-2 proteins the most promising therapeutic target in AML.

Fig. 1

a Primary AML samples were treated with indicated concentrations of ABT-199, A1331852 or S63845 for 20 h. Cell death was measured by FACS analysis using Annexin-V/FITC staining in combination with anti-CD45/APC staining. Mean of each experiment performed in duplicate or triplicate is shown. b Eleven AML cell lines were treated with indicated concentrations of ABT-199, A1331852 or S63845 for 72 h prior to analysis of viability using CellTiter-Glo. Data shown are mean and standard error of mean (n = 3–7).